Nesiritide is a peptide drug that illustrates something this site's guides return to often: FDA approval and widespread clinical use aren't the same thing. The drug remains approved, but post-marketing research changed how, and how often, physicians reach for it.
What It Is
Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), a hormone the heart's ventricles naturally release in response to volume overload and pressure. The synthetic version, sold as Natrecor, is manufactured using recombinant DNA technology in E. coli, a production method this site's guide to peptide manufacturing describes in more detail, the same general approach used for several other approved peptide hormones.
FDA-Approved Use
Nesiritide received FDA approval in 2001 for the intravenous treatment of acutely decompensated congestive heart failure in patients with shortness of breath at rest or with minimal activity. It's strictly a hospital-administered, short-term IV infusion for acute symptom relief, not an outpatient or chronic therapy, and it has no role in stable, well-managed heart failure.
How It Works
As a BNP analog, nesiritide binds to natriuretic peptide receptors on blood vessels and the kidneys, producing vasodilation (widening of blood vessels) and promoting sodium and fluid excretion. The intended effect is to rapidly ease the heart's workload and relieve congestion in patients hospitalized with acute, severe heart failure symptoms.
Why Its Use Declined After Approval
In the years following approval, several meta-analyses and observational studies raised concerns that nesiritide might be associated with worsening kidney function and, in some analyses, increased short-term mortality compared with standard care. These findings prompted updated safety labeling and led many hospitals and cardiologists to scale back its use substantially in favor of more established therapies like IV diuretics and vasodilators. A large, FDA-mandated outcomes trial, ASCEND-HF, published in 2011, found nesiritide did not significantly increase mortality or worsen kidney function compared with placebo, but it also didn't demonstrate a clear reduction in death or hospital readmission, evidence that didn't fully resolve the controversy or restore the drug to its earlier usage levels.
Current Status
Nesiritide remains FDA-approved and commercially available; it was never withdrawn from the market over the safety signals described above. It's simply used far more selectively today than it was immediately after its 2001 approval, generally reserved for specific acute cases rather than used as routine first-line therapy. In practice, that typically means patients with severe, refractory congestion who haven't responded adequately to standard intravenous diuretics, rather than broad use across every heart failure admission. It serves as a useful, concrete case study in why large post-marketing outcomes trials matter, and why a drug's approval status alone doesn't tell you how a drug is actually used in current clinical practice.
The Bottom Line
Nesiritide is an FDA-approved peptide hormone analog for acute, hospital-based heart failure care, administered and monitored entirely by hospital clinicians, not a treatment a patient would ever self-administer or seek out directly. Its post-approval history is a reminder that the evidence base supporting a drug's safe use keeps accumulating well after the FDA's initial approval decision, sometimes narrowing how a drug ends up being used in practice.